Understand the source comparison
Comparison to Established Arthritis Therapies
Cartalax (tripeptide) Upregulates TIMP-1, reduces MMP-13 expression intracellularly In vitro and rat model only. No human RCTs with arthritis endpoints Unknown in humans Not FDA-approved; available as research compound Mechanistic promise without clinical vali
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cartalax (tripeptide)
- Upregulates TIMP-1, reduces MMP-13 expression intracellularly
- In vitro and rat model only. No human RCTs with arthritis endpoints
- Unknown in humans
- Not FDA-approved; available as research compound
- Mechanistic promise without clinical validation
- NSAIDs (ibuprofen, naproxen)
- COX enzyme inhibition. Reduces prostaglandin synthesis
- No cartilage-protective effects; may accelerate cartilage loss long-term
- 30–60 minutes for pain relief
- FDA-approved
- Symptom management only. Does not slow disease
- Hyaluronic acid injections
- Viscosupplementation. Temporary joint lubrication
- Conflicting data; AAOS guidelines state insufficient evidence for structural benefit
- 2–4 weeks (if effective)
- FDA-approved for symptomatic relief
- Pain relief in ~50% of patients; no proven DMOAD effect
- Sprifermin (FGF-18 analog)
- Stimulates chondrocyte proliferation and matrix synthesis
- Phase II trials showed dose-dependent cartilage thickness increases (0.03–0.05mm at two years)
- Not yet marketed. Cartilage endpoint only
- Phase III trials ongoing
- First biologic with imaging-confirmed cartilage regeneration
- Platelet-rich plasma (PRP)
- Growth factor delivery to stimulate endogenous repair
- Mixed results; meta-analyses show modest pain improvement but no MRI-confirmed cartilage changes
- 4–8 weeks
- Not FDA-approved; used off-label
- Evidence quality is low due to protocol variability